8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2009

CLINICAL DATA, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State of Incorporation) 000-12716
(Commission File Number) 04-2573920
(IRS Employer
Identification No.)

One Gateway Center, Suite 702, Newton, Massachusetts
(Address of Principal Executive Offices) 02458
(Zip Code)

Registrant’s telephone number, including area code: (617) 527-9933

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Clinical Data, Inc. (the “Company”) is furnishing presentation materials, included as Exhibit 99.1 to this current report and incorporated herein by reference, which the Company will present at the Rodman & Renshaw Annual Global Investment Conference in New York, New York on September 9, 2009. The Company expressly disclaims any obligation to update this presentation and cautions that it is only accurate on the date it is presented. The inclusion of any data or statements in this presentation does not signify that the information is considered material.

Caution Regarding Forward-Looking Statements.

This filing and the documents that are incorporated by reference herein contain forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the Company’s estimates and assumptions and are subject to a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the Company’s ability to successfully integrate the operations, business, technology and intellectual property obtained in acquisitions; the Company’s ability to obtain regulatory approval for, and successfully introduce, new products; the Company’s ability to expand long-term business opportunities; the Company’s ability to maintain normal terms with customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Forward-looking statements also include those preceded or followed by the words “anticipates,” “believes,” “estimates,” “expects,” “hopes,” “targets” or similar expressions. For each of these forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of performance. The future results of the Company could be affected by subsequent events and could differ materially from those expressed in the forward-looking statements. If future events and actual performance differ from the Company’s assumptions, the Company’s actual results could vary significantly from the performance projected in the forward-looking statements. Except for ongoing obligations to disclose material information under the federal securities laws, the Company undertakes no obligation to disclose any revisions to any forward-looking statements or to report events or circumstances after the date of this filing.

You should understand that the following factors could affect the future results of the Company, and could cause those results to differ materially from those expressed in the forward-looking statements:

• whether vilazodone and apadenoson will advance further in the clinical trials process and whether and when, if at all, vilazodone and apadenoson will receive final approval from the U.S. Food and Drug Administration and equivalent foreign regulatory agencies and for which indications;

• whether vilazodone and apadenoson will be successfully marketed if approved;

• the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety;

• the Company’s ability to achieve the expected synergies and operating efficiencies from all of its acquisitions;

• the strength of the Company’s intellectual property rights;

• competition from pharmaceutical, biotechnology and diagnostics companies;

• the development of and the Company’s ability to take advantage of the market for pharmacogenomic and biomarker products and services;

• general economic downturns; and

• other risks contained in the Company’s various SEC reports and filings, including but not limited to the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2009, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 and the Company’s subsequent Current Reports on Form 8-K filed with the Securities and Exchange Commission.

The Company wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made, and wishes to advise readers that the factors listed above could affect our financial performance and could cause actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Conference Presentation dated September 9, 2009

We are furnishing the exhibit to this Form 8-K in accordance with Item 7.01, Regulation FD Disclosure. The exhibit shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Clinical Data, Inc.
By:	/s/ Caesar J. Belbel
	Caesar J. Belbel
	Executive Vice President, Chief Legal Officer and Secretary

DATE: September 9, 2009

EXHIBIT INDEX

Exhibit No.	Description
99.1	Conference Presentation dated September 9, 2009

EX-99.1

1 Rodman & Renshaw Global Investment Conference September 9, 2009

Forward-Looking Statement 2 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding: our ability to successfully develop and commercialize our therapeutic products; our ability to introduce our new pharmacogenetic and molecular diagnostics products; our ability to successfully integrate the operations, business, technology, and intellectual property obtained in our acquisitions; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether vilazodone, Stedivaze or any of our other therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration and equivalent foreign regulatory agencies and for which indications; whether our PGxPredict and FAMILION diagnostic tests will gain wide acceptance in the market; whether we will be able to successfully identify and validate biomarkers for response to vilazodone or to any of our other therapeutic products; whether vilazodone, Stedivaze and our other therapeutic products will be successfully marketed if approved; the extent to which genetic markers are predictive of clinical outcomes and drug efficacy and safety; our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Annual Report on Form 10-K for the fiscal year ended March 31, 2009, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, and our Current Reports on Form 8-K filed from time to time with the Securities and Exchange Commission. Our audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Investment Opportunity Clinical Data is a biotechnology company developing late-stage drugs that are first-in-class, best-in-category 3 Central Nervous System Cardiovascular Disease Oncology

Current Value Drivers Two Phase III drugs: Vilazodone(tm): first-in-class dual acting serotonergic antidepressant Stedivaze(tm): potential best-in-class drug used as a vasodilator for cardiac stress testing Deep pipeline of drugs and biomarker candidates Genetic testing business for inherited cardiac conditions 4

Depression is Largest Segment of CNS Market U.S. market continues to grow1 $12B annual sales 208M+ prescriptions Medical cost to treat depression is close to $30B annually2 Vilazodone relevant market SSRIs (i.e. Zoloft(r), Lexapro(r), Celexa(r), Prozac(r)) SNRIs (i.e. Cymbalta(r), Effexor(r)XR, Pristiq(r)) All formulations of Wellbutrin(r) and generics 5 1 IMS Health's National Prescription Audit and National Sales Perspective 2 National Institute of Mental Health (NIMH), 2000

New Options Needed in Treatment of Depression Majority of patients do not achieve success with 1st therapy1 Side effects are common, tolerability is a challenge Co-morbid conditions often require additional medications 40% of depressed patients have anxiety Patient compliance remains poor 6 1 STAR*D Study, January, 2006 American Journal of Psychiatry

Vilazodone for Treatment of Depression First-in-class antidepressant with a dual serotonergic mechanism of action SSRI 5HT1A Demonstrated superiority to placebo in 2 Phase III trials Well-tolerated with low discontinuation rate Sexual function is similar to placebo as measured by validated scales Opportunity for additional indications, e.g. anxiety disorders 7 Established in treatment of depression, anxiety and other psychiatric conditions

Requirements for NDA Submission FDA requires demonstration of: Acceptable risk/benefit ratio Statistical significance in two adequately powered controlled trials Robust results on multiple measures using multiple analytic methods (MADRS, HAMD, CGI) Safety in both acute and chronic administration Database >2,200 patients, includes long-term exposure Completed required studies including ECG effects, drug-drug interaction, PK, food effect Successful commercial scale-up for API and tablets Updated timing for NDA submission is 1Q calendar 2010 8

2nd Phase III Trial Confirms Superiority to Placebo 9 Least Squares Mean Change at Week 8 Least Squares Mean Change at Week 8 LS Mean Treatment Difference p-value 1st Phase III Vilazodone N = 198 Placebo N = 199 MADRS -12.9 -9.6 -3.2 0.001 HAMD17 -10.4 -8.6 -1.7 0.022 HAMA -6.5 -5.2 -1.4 0.031 2nd Phase III Vilazodone N = 231 Placebo N = 231 MADRS -13.3 -10.8 -2.5 0.009 HAMD17 -10.7 -9.1 -1.6 0.026 HAMA -7.0 -5.7 -1.2 0.037

Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* AE Drug Placebo Nausea 26% 12% Diarrhea/ loose stools 18% 9% Somnolence 13% 6% Tremor 11% 3% Sweating Increased 8% 3% Ejaculation failure 7% <1% Dyspepsia 6% 3% Vilazodone Phase III Trials** Vilazodone Phase III Trials** Vilazodone Phase III Trials** AE Drug Placebo Diarrhea 28% 9% Nausea 23% 5% Dizziness 8% 3% Insomnia 6% 2% Lexapro(r) (escitalopram oxalate)* Lexapro(r) (escitalopram oxalate)* Lexapro(r) (escitalopram oxalate)* AE Drug Placebo Nausea 15% 7% Insomnia 9% 4% Ejaculation Disorder 9% <1% Somnolence 6% 2% Sweating Increased 5% 2% Fatigue 5% 2% Effexor(r) XR (venlafaxine hydrochloride)* Effexor(r) XR (venlafaxine hydrochloride)* Effexor(r) XR (venlafaxine hydrochloride)* AE Drug Placebo Nausea 31% 12% Dizziness 20% 9% Somnolence 17% 8% Abnormal ejaculation 16% <1% Sweating 14% 3% Dry Mouth 12% 6% Nervousness 10% 5% Anorexia 8% 4% Abnormal dreams 7% 2% Tremor 5% 2% Diarrhea and nausea were mild to moderate, early in treatment and resolved quickly 10 Most Common Adverse Events*

Low Discontinuation Rates in Phase III Studies 11 1st Phase III Trial 1st Phase III Trial 2nd Phase III Trial 2nd Phase III Trial Vilazodone Placebo Vilazodone Placebo Enrolled 205 205 240 241 Discontinued 53 (25.9%) 51 (24.9%) 47 (19.6%) 46 (19.1%) Adverse Event 19 (9.3%) 10 (4.9%) 12 (5.1%) 4 (1.7%) Diarrhea 4 0 0 0 Nausea/Vomiting 0 1 3 0 Palpitations 3 0 1 0 Suicide/Suicidal Ideation 0 3 0 0 Lack of Therapeutic Effect 4 (2.0%) 9 (4.4%) 3 (1.3%) 7 (2.9%) Other1 30 (14.6%) 32 (15.7%) 32 (13.3%) 35 (14.5%) 1'Other' includes withdrawal of consent, lost to follow-up, investigator decision, non-compliance

Sexual Dysfunction is Common in Depression 40 to 50% of depressed patients report sexual dysfunction1 Drug-induced SD is common with antidepressants Reliance on spontaneous reporting significantly underestimates incidence 65% of physicians felt lack of drug-induced SD was extremely important when choosing a depression drug2 12 1 Kennedy SH, Dickens SE, et al. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord. 1999;56:201-208 2 Clinical Data, Inc. Market Research, 2009

13 Vilazodone Impact on Overall Sexual Function Comparable to Placebo in 2nd Phase III Trial 13 Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Treatment Week 8 Week 24 Week 52 Males Placebo 1.8 Vilazodone 0.6 LTSS* Vilazodone 1.5 1.7 2.6 Females Placebo 2.3 Vilazodone 1.9 LTSS Vilazodone 2.3 3.4 4.5 *Long -Term Safety Trial not placebo controlled Females 122 137 399

Market Decile Number of Prescribers Minimum TRx Maximum TRx Average TRx Cum. % of Prescribers Cum. % of TRx 10 3,517 3,545 28,320 5,123 0.5% 10.0% 9 6,437 2,342 3,545 2,800 1.5% 20.0% 8 8,890 1,792 2,341 2,027 2.9% 30.0% 7 11,245 1,445 1,792 1,603 4.7% 40.0% 6 13,864 1,174 1,445 1,300 6.8% 50.0% 5 17,141 940 1,174 1,051 9.5% 60.0% 4 21,863 718 940 824 12.8% 70.0% 3 30,136 491 718 598 17.5% 80.0% 2 50,445 248 491 357 25.3% 90.0% 1 482,539 0 248 37 100.0% 100.0% Depression Market is Highly Concentrated to Top Prescribers 14 IMS Health Xponenet April 2009 < 13% of prescribers (82,957) accounted for 70% of prescriptions

Depression Drugs Compete in Generic Market 15 Quarterly Sales 2003 - 2008 SSRIs: Zoloft(r), Lexapro(r), Celexa(r) - SNRIs: Cymbalta(r), Effexor(r)XR, IMS HEALTH'S National Sales Perspective Celexa(r) goes generic (10/04) Zoloft(r) goes generic (7/06)

Vilazodone Addresses Unsatisfied Market Favorable physician acceptance in market research1 Received a 7/10 rating Over 60% would probably or definitely prescribe vilazodone Commercial preparations underway to maximize potential from product approval to first prescription Several approaches to commercialize with significant ROI 1Clinical Data, Inc. Market Research: Physician Survey, 2009 16

Stedivaze: Vasodilator for Cardiac Stress Testing U.S. market projected to be $800M in 20111 Potential best-in-class vasodilator Phase II data demonstrated: Improved tolerability over existing agents Rapid onset and offset of action Diagnostic accuracy Ease of use via fixed bolus dosing 17 1 AMR Monthly Monitor

Stedivaze AE Profile is Better than Adenoscan in Phase II Trial Hendel et al AHA, 2005 *Safety population only. Incidence of AEs 5% or greater. 18 Dyspnea Chest Pain Dizziness Headache Flushing Hypotension Nausea 2° AV Block % with AEs Adenoscan 0 20 40 N = 124 Stedivaze (Apadenoson) 1.0 ^g/kg 2.0 ^g/kg N = 61 N = 63

Stedivaze Clinical Development Program Initiated Phase I studies in chronic obstructive pulmonary disease and asthma to demonstrate safety Marketed adenosine agonists carry a warning or are contra- indicated in patients with COPD and asthma Increased selectivity of Stedivaze may permit safe use in these patients Initiating Phase III trials Revising trial protocol to reflect recent feedback Phase III program to begin before calendar year end 2009 19

Therapeutics Pipeline Current Stage Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Novartis Confidential Partner Vilazodone(tm) Major Depression Stedivaze(tm) Cardiac Stress Testing ATL1222: Acute Inflammation ATL844: Diabetes / Asthma ATL313 : Ophthalmic Oncology Pain AVN316: Oncology Projected Stage In 12 Months 20 CombinatoRx

Dx for Inherited Cardiac Conditions: FAMILION(r) Over 100% Growth Year Over Year* *Calendar Year 21 $0 $.5 $1 $1.5 $2 $2.5 2004 2005 2006 2007 2008 New Sales Force $ (Millions) $3 2009 $3.5 $4

Clinical Data (CLDA) Profile* 22 Revenue: $ 3.7M (3 mos.) $10.4M (Year ended 3/31/09) Cash & Marketable Securities: $52.4M Debt: $51.7M** Shares Outstanding: 23.5M Insider Ownership: ~ 50% Substantially all shares purchased *As of 6/30/09 unless otherwise indicated **Net of unamortized discount of $20.8 M

Upcoming Events Submit vilazodone NDA to the FDA and continue preparations for commercialization Complete Phase I studies for Stedivaze in COPD and asthma; start Phase III program in 4Q calendar 2009 Establish partnerships for other preclinical programs 23

24 Thank You